Literature DB >> 6388819

Transplantation of non-purified autologous bone marrow in patients with AML in first remission.

B Löwenberg, J Abels, D W van Bekkum, G Dzoljic, A Hagenbeek, W D Hendriks, J van de Poel, W Sizoo, K Sintnicolaas, G Wagemaker.   

Abstract

Four patients with acute myeloid leukemia (AML) were treated with high-dose cyclophosphamide and total body irradiation followed by reinfusion of a portion of their own bone marrow collected during remission. This procedure was applied when the patients were in complete remission. They did not receive further maintenance chemotherapy after grafting. The use of bone marrow for grafting that had been pre-exposed to high-dose chemotherapy for remission induction did not preclude good hematologic regeneration. All patients showed stable remissions that lasted for 64+, 21, 40+, and 19+ months, respectively. Death in the second patient was due to a medullary relapse of the leukemia. Autologous bone marrow transplantation in patients with AML in remission may permit lasting remissions, even when applied without additional chemotherapy and attempts to purify the marrow of neoplastic cells.

Entities:  

Mesh:

Year:  1984        PMID: 6388819     DOI: 10.1002/1097-0142(19841215)54:12<2840::aid-cncr2820541204>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.

Authors:  A Hagenbeek; A C Martens
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells.

Authors:  Lihui Wen; Myriam Labopin; Manuela Badoglio; Dandan Wang; Lingyun Sun; Dominique Farge-Bancel
Journal:  Stem Cells Int       Date:  2019-05-02       Impact factor: 5.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.